Neurofibromatosis Type 1 Revisited

被引:432
|
作者
Williams, Virginia C. [1 ,2 ]
Lucas, John [1 ,2 ]
Babcock, Michael A. [1 ,2 ]
Gutmann, David H. [3 ]
Korf, Bruce [4 ]
Maria, Bernard L. [1 ,2 ]
机构
[1] Med Univ S Carolina, Dept Pediat, Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Neurosci, Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA
[3] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[4] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA
关键词
neurofibromatosis type 1; neurofibroma; malignant peripheral nerve sheath tumor; neurofibromin; BONE-MINERAL DENSITY; NERVE SHEATH TUMORS; POSITRON-EMISSION-TOMOGRAPHY; PLEXIFORM NEUROFIBROMA; COGNITIVE DEFICITS; CLINICAL-FEATURES; NATURAL-HISTORY; MOUSE MODEL; FDG PET; PHASE-I;
D O I
10.1542/peds.2007-3204
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with a worldwide incidence of similar to 1 per 2500 to 3000 individuals. Caused by a germ-line inactivating mutation in the NF1 gene on chromosome 17, the disease is associated with increased morbidity and mortality. In the past several years, significant progress has been made in standardizing management of the major clinical features of neurofibromatosis type 1. Moreover, improved understanding of how the neurofibromatosis type 1 protein, neurofibromin, regulates cell growth recently provided insight into the pathogenesis of the disease and has led to the development of new therapies. In this review, we describe the clinical manifestations, recent molecular and genetic findings, and current and developing therapies for managing clinical problems associated with neurofibromatosis type 1. Pediatrics 2009; 123: 124-133
引用
收藏
页码:124 / 133
页数:10
相关论文
共 50 条
  • [21] The Use of PET in the Evaluation of Tumors in Children with Neurofibromatosis Type 1
    Fisher, Michael J.
    PET CLINICS, 2008, 3 (04) : 531 - +
  • [22] Cutaneous manifestations in neurofibromatosis type 1
    Miraglia, E.
    Moliterni, E.
    Lacovino, C.
    Roberti, V
    Laghi, A.
    Moramarco, A.
    Giustini, S.
    CLINICA TERAPEUTICA, 2020, 171 (05): : E371 - E377
  • [23] Spinal manifestations of Neurofibromatosis type 1
    Shofty, Ben
    Barzilai, Ori
    Khashan, Morsi
    Lidar, Zvi
    Constantini, Shlomi
    CHILDS NERVOUS SYSTEM, 2020, 36 (10) : 2401 - 2408
  • [24] Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis
    Woodruff, JM
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1999, 89 (01): : 23 - 30
  • [25] Human stem cell modeling in neurofibromatosis type 1 (NF1)
    Wegscheid, Michelle L.
    Anastasaki, Corina
    Gutmann, David H.
    EXPERIMENTAL NEUROLOGY, 2018, 299 : 270 - 280
  • [26] Therapeutics for Childhood Neurofibromatosis Type 1 and Type 2
    Simone L. Ardern-Holmes
    Kathryn N. North
    Current Treatment Options in Neurology, 2011, 13 : 529 - 543
  • [27] Neurofibromatosis type 1
    Anders, Rebecca
    Hirsch, Franz Wolfgang
    Roth, Christian
    PAEDIATRIE UND PAEDOLOGIE, 2024, 59 (02): : 95 - 103
  • [28] Neurofibromatosis type 1
    North, K
    AMERICAN JOURNAL OF MEDICAL GENETICS, 2000, 97 (02): : 119 - 127
  • [29] Neurofibromatosis 1
    Ferner, Rosalie E.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2007, 15 (02) : 131 - 138
  • [30] Neurofibromatosis 1
    Rosalie E Ferner
    European Journal of Human Genetics, 2007, 15 : 131 - 138